Registro de fonte primária
Perspective Therapeutics presented additional analyses from its ongoing Phase 1/2a trial of bamzireotide navoxetan (VMT-α-NET) showing improved efficacy signals in the SSTR2+ GEP-NET subgroup (ORR 39%, DCR 95%, 18-month PFS 75%) compared to prior data and an approved radiotherapy. The company is incorporating an enrichment strategy into regulatory discussions and targets an End-of-Phase 2 meeting in Q1 2027 to enable Phase 3 initiation in 2027.
EX-99.1 2 catx-ex99_1.htm EX-99.1 EX-99.1 Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs • Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations • Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population • Bamzireotide continues to be well-tolerated • Targeting End-of-Phase 2 meeting in 1Q 2027 SEATTLE, November 5, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” t
CATX reports positive Phase 1/2a interim data for VMT-α-NET at ESMO 2026
Perspective Therapeutics apresentará análise de dados do VMT-α-NET na ASCO 2026